Clinical Application of Lobaplatin Combined with Docetaxel in Adjuvant Chemotherapy for Triple-Negative Breast Cancer in Elderly Patients

To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients.A total of 96 elderly triple-negative breast cancer patients admitted to our hospital from January 2008 to December 2011 were randomly divided into two groups.A group of 56 patients received docetaxel 75 mg·m^(-2),intravenous drip,d1;lobaplatin 30 mg·m^(-2),intravenous drip,d1;21 days repeat,a total of 6 cycles.A group of 40 patients received chemotherapy for 6 cycles with an anthracycline-containing(TEC)regimen.Comparison of adverse reactions and 5-year diseasefree survival in both groups.The incidence of thrombocytopenia was significantly higher in 56 patients with TL regimen than those with TCE-containing anthracyclines(P=0.005).But the incidence of cardiotoxicity was 32.5%in the TEC group.And the difference was statistically significant(P=0.008).The 5-year disease-free survival rate was 73.2%in the TL group and 67.5%in the TEC group.There was no statistical difference.Docetaxel combined with lobaplatin in the treatment of elderly triple-negative breast cancer has no significant difference in efficacy compared with traditional anthracycline-containing drugs,but it can avoid the cardiotoxicity caused by anthracyclines.It’s a new option for elderly TNBC adjuvant chemotherapy,suggesting to expand the sample content for further research.

Knowledge level of cardio-oncology in oncologist and cardiologist:a survey in China

To the Editor:Cancer has been the leading cause of death worldwide and in China since 2010.[1]As advances are made in the treatment of cancer,the survival rate of cancer improves;at the same time,many cancer patients and cancer survivors suffer from cardiovascular disease(CVD)as a result of intense anticancer treatment.[2-4]To prevent and treat cardiovascular problems mediated by cancer treatments,a new medical discipline called cardiooncology was established.Although the field of cardiooncology has existed for 20 years,[5]its development in China is still in the early stages.